Kintara Therapeutics (KTRA)
(Real Time Quote from BATS)
$0.17 USD
+0.01 (7.60%)
Updated Apr 26, 2024 10:08 AM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Kintara Therapeutics, Inc falls in the month of June.
All items in Millions except Per Share data.
6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 | 6/30/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 2 | 12 | 11 | 2 | 4 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 2 | 1 | 1 | 0 | 0 |
Total Current Assets | 3 | 13 | 12 | 3 | 4 |
Net Property & Equipment | 1 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 3 | 2 | 0 | 0 |
Total Assets | 4 | 16 | 14 | 3 | 4 |
Liabilities & Shareholders Equity | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 | 6/30/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 3 | 2 | 2 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 1 | 1 | 1 | 0 |
Total Current Liabilities | 3 | 4 | 3 | 3 | 2 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 3 | 4 | 3 | 3 | 2 |
Shareholders Equity | 6/30/2023 | 6/30/2022 | 6/30/2021 | 6/30/2020 | 6/30/2019 |
---|---|---|---|---|---|
Preferred Stock | 11 | 13 | 15 | 5 | 5 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 141 | 136 | 107 | 57 | 51 |
Retained Earnings | -151 | -136 | -111 | -70 | -61 |
Other Equity | 0 | 0 | 0 | 9 | 7 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 1 | 12 | 11 | 0 | 2 |
Total Liabilities & Shareholder's Equity | 4 | 16 | 14 | 3 | 4 |
Total Common Equity | -10 | -1 | -4 | -5 | -3 |
Shares Outstanding | 1.60 | 1.30 | 0.60 | 0.20 | 0.00 |
Book Value Per Share | -6.20 | -0.58 | -7.25 | -22.70 | -3.01 |
Fiscal Year End for Kintara Therapeutics, Inc falls in the month of June.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 1 | 0 | 2 | 3 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 0 | 1 | 2 | 3 |
Total Current Assets | NA | 1 | 1 | 3 | 6 |
Net Property & Equipment | NA | 1 | 1 | 1 | 1 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 2 | 1 | 4 | 7 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 2 | 3 | 3 | 3 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 0 | 0 | 0 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 2 | 3 | 3 | 3 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 2 | 4 | 3 | 3 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 10 | 11 | 11 | 11 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 145 | 142 | 141 | 141 |
Retained Earnings | NA | -156 | -155 | -151 | -148 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 0 | -2 | 1 | 4 |
Total Liabilities & Shareholder's Equity | NA | 2 | 1 | 4 | 7 |
Total Common Equity | 0 | -10 | -13 | -10 | -7 |
Shares Outstanding | 39.00 | 10.10 | 1.70 | 1.60 | 1.60 |
Book Value Per Share | 0.00 | -1.03 | -7.44 | -6.20 | -4.29 |